Corbus Pharmaceuticals Holdings (STU:3371) Short Interest


STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
31 GF Score
Price €7.57
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:3371 vs AGEN, HURA, SLNCF: Short Interest Comparison

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Short Interest falls into.


STU:3371
31GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score

Get the complete analysis for STU:3371

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.57
Price